Last close As at 06/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Consumer
Treatt
Written by
Treatt |
Staying sweet |
FY16 results |
Food & beverages |
30 November 2016 |
Share price performance
Business description
Next events
Analysts
Treatt is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
Results have yet again beaten our forecasts and the management has now delivered the fourth consecutive year of earnings above expectations. The share price is up 41% over the last three months, and Treatt is steadily moving from commoditised sales to more value-added products. Its strategy of deep customer relationships is paying off, giving it a real competitive advantage and improving margins. The year finished strongly and momentum is due to continue in the traditionally seasonally weaker Q117. Our P&L forecasts are broadly maintained, but our fair value moves to 272p (from 240p) as a result of stronger cash flow.
Year |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
09/15 |
85.9 |
8.3 |
12.7 |
4.0 |
20.8 |
1.5 |
09/16 |
88.0 |
9.6 |
14.3 |
4.4 |
18.5 |
1.6 |
09/17e |
92.4 |
10.3 |
15.2 |
4.6 |
17.4 |
1.7 |
09/18e |
96.1 |
10.6 |
15.7 |
4.7 |
16.8 |
1.8 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
From strength to strength
FY16 sales were in line and operating profit was 3% above our forecasts, but this was despite a net FX loss during the year. We expect the strong momentum from Q4 to continue into Q1 (which is usually seasonally weaker) and contribute towards further margin improvement. We leave our forecasts broadly unchanged, but see potential for upside given management’s conservative track record.
Clear focus
Treatt outlined its new strategy towards the end of FY15, and it was an evolution from the previous three-year plan, being implemented by the same management team. CEO Daemmon Reeve previously reshaped the business to break down the silo mentality, and the goal now is to achieve improved customer focus and closer relationships, with the ultimate aim of moving Treatt away from commoditised trading and concentrating its resources further up the value chain to deliver greater profitability. The results so far are clear, as the business continues to go from strength to strength.
Valuation: Attractive ingredients play
We value Treatt using a DCF model and we derive a fair value of 272p (previously 240p), or c 4% upside to the current share price. The increase in fair value reflects a combination of stronger than expected cash flow and our assumption of slightly lower working capital outflows in future years; albeit allowing for relatively high levels of inventory, which act as a buffer against commodity price movements. Given the relatively high level of working capital, the DCF valuation is sensitive to small movements in our forecast. On a relative valuation, Treatt trades at 17.2x and 11.9x calendar P/E and EV/EBITDA multiples for 2017, representing a c 20% discount to its ingredients peer group on both metrics.
FY16 results
FY sales were up 2.5%, profit before tax was up 11% on an adjusted basis, and adjusted diluted EPS was up 7%. The drive towards higher value-added products helped improve gross margins, and this continues to be an area of focus for the group. Strategically, the main objective is to collaborate ever more closely with its customers, in order to deliver superior solutions and become the supplier of choice, thus leading to long-term, sustainable profit growth. The group has invested in innovation and staff development, and more recently on growing its activities in China, where it sees great potential and hence has increased its capabilities. Net debt continued to fall and stood at £1.7m at the end of FY16. It is likely to increase from here once the UK site relocation goes ahead.
UK site relocation
As announced with the H115 results, Treatt has decided to fully relocate its UK head office and manufacturing plant in the Bury St Edmunds area to a new site nearby. Discussions with landowners are at an advanced stage, and we expect an update within the next few months. We previously forecast £20m total spend on this project, with the majority of the costs in FY17 and FY18. We have now increased this to £28m in total. Part of the increase is due to the expectation that new technologies will be incorporated into the new facility, but there is also an increase due to effectively deferred capex. The company has now guided towards a £3-5m outflow due to capital projects that have been held back over the last three years and that will be implemented once the relocation occurs. Indeed FY16 capex stood at particularly low levels (£0.7m) and reflects the fact that management has sensibly reduced capital expenditure to the minimum possible in view of the imminent relocation.
Valuation
We illustrate Treatt’s valuation versus its ingredients peer group in Exhibit 1 below. Treatt trades at a discount to its ingredients peer group on all metrics.
Exhibit 1: Benchmark valuation
Market cap |
P/E (x) |
EV/EBITDA (x) |
Dividend yield (%) |
||||
2017e |
2018e |
2017e |
2018e |
2016e |
2017e |
||
Givaudan |
CHF18,107 |
23.6 |
22.4 |
15.7 |
14.9 |
2.9% |
3.2% |
IFF |
$10,938 |
22.7 |
20.3 |
14.9 |
13.7 |
1.7% |
1.9% |
Symrise |
CHF9,145 |
25.5 |
23.4 |
14.3 |
13.0 |
1.3% |
1.5% |
Frutarom |
NIS11,705 |
20.2 |
18.9 |
13.9 |
12.1 |
0.6% |
0.7% |
Chr Hansen |
DKK51,040 |
31.5 |
27.9 |
20.7 |
18.7 |
1.3% |
1.5% |
Kerry |
€12,264 |
19.6 |
17.5 |
14.0 |
12.2 |
0.8% |
0.9% |
Ingredion |
$9,580 |
18.0 |
16.7 |
9.7 |
9.0 |
1.4% |
1.5% |
Peer group average |
23.0 |
21.0 |
14.8 |
13.4 |
1.4% |
1.6% |
|
Treatt |
£136.1 |
17.2 |
16.7 |
11.9 |
11.3 |
1.7% |
1.8% |
Premium/(discount) to peer group (%) |
-25.2% |
-20.3% |
-19.2% |
-15.5% |
15.9% |
9.6% |
|
Source: Bloomberg (prices as of 28 November 2016). Note: Treatt figures are calendarised to aid comparison.
Our DCF-derived fair value moves to 272p (from 240p). This is predicated on a WACC of 8.0% (encompassing a beta of 0.8, an equity risk premium of 5.0% and a borrowing spread of 5.0%) and a terminal growth rate of 2%. The increase in fair value is due to stronger than expected cash flow resulting in lower net debt in FY16, and the improved cash flow feeding through into our forecasts and hence slightly lower working capital outflows in future years. The business will still operate with relatively high levels of inventory to guarantee supply and protect itself from commodity price movements, but we see some scope for a small improvement in the metrics.
Exhibit 2: Financial summary
£000s |
2013 |
2014 |
2015 |
2016 |
2017e |
2018e |
||
Year-end September |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||||
Revenue |
|
|
74,097 |
79,189 |
85,934 |
88,040 |
92,442 |
96,140 |
Cost of Sales |
(56,510) |
(61,218) |
(66,955) |
(67,639) |
(72,403) |
(75,203) |
||
Gross Profit |
17,587 |
17,971 |
18,979 |
20,401 |
20,039 |
20,937 |
||
EBITDA |
|
|
8,360 |
9,068 |
10,307 |
11,604 |
12,421 |
13,098 |
Operating Profit (before amort., except and sbp.) |
|
|
7,141 |
7,846 |
9,063 |
10,257 |
10,880 |
11,496 |
Intangible Amortisation |
(181) |
(172) |
(175) |
(142) |
(160) |
(160) |
||
Share based payments |
(22) |
(46) |
(198) |
(566) |
(652) |
(673) |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
||
Operating Profit |
6,938 |
7,628 |
8,690 |
9,549 |
10,068 |
10,663 |
||
Net Interest |
(651) |
(724) |
(740) |
(703) |
(559) |
(851) |
||
Exceptionals |
(1,153) |
(1,402) |
(174) |
(553) |
0 |
0 |
||
Profit Before Tax (norm) |
|
|
6,490 |
7,122 |
8,323 |
9,554 |
10,321 |
10,645 |
Profit Before Tax (FRS 3) |
|
|
5,134 |
5,502 |
7,776 |
8,293 |
9,509 |
9,812 |
Profit Before Tax (company) |
|
|
6,287 |
6,904 |
7,950 |
8,846 |
9,509 |
9,812 |
Tax |
(1,655) |
(1,553) |
(1,786) |
(2,144) |
(2,425) |
(2,502) |
||
Profit After Tax (norm) |
4,835 |
5,326 |
6,537 |
7,410 |
7,896 |
8,143 |
||
Profit After Tax (FRS 3) |
3,479 |
3,949 |
5,990 |
6,149 |
7,084 |
7,310 |
||
Average Number of Shares Outstanding (m) |
51.1 |
51.3 |
51.5 |
51.9 |
51.9 |
51.9 |
||
EPS - normalised (p) |
|
|
9.5 |
10.4 |
12.7 |
14.3 |
15.2 |
15.7 |
EPS - normalised & fully diluted (p) |
|
|
9.4 |
10.3 |
12.6 |
14.1 |
15.0 |
15.5 |
EPS - (IFRS) (p) |
|
|
6.8 |
7.7 |
11.6 |
11.8 |
13.7 |
14.1 |
Dividend per share (p) |
3.7 |
3.8 |
4.0 |
4.4 |
4.6 |
4.7 |
||
Gross Margin (%) |
23.7 |
22.7 |
22.1 |
23.2 |
21.7 |
21.8 |
||
EBITDA Margin (%) |
11.3 |
11.5 |
12.0 |
13.2 |
13.4 |
13.6 |
||
Operating Margin (before GW and except.) (%) |
9.6 |
9.9 |
10.5 |
11.7 |
11.8 |
12.0 |
||
BALANCE SHEET |
||||||||
Fixed Assets |
|
|
14,341 |
13,777 |
13,381 |
16,161 |
22,347 |
40,027 |
Intangible Assets |
1,759 |
1,801 |
1,736 |
3,364 |
3,204 |
3,044 |
||
Tangible Assets |
11,718 |
10,994 |
10,998 |
11,361 |
17,707 |
35,547 |
||
Investments |
864 |
982 |
647 |
1,436 |
1,436 |
1,436 |
||
Current Assets |
|
|
38,340 |
43,590 |
45,045 |
54,435 |
49,626 |
50,437 |
Stocks |
23,669 |
28,020 |
25,799 |
29,990 |
30,565 |
30,826 |
||
Debtors |
13,207 |
14,509 |
17,635 |
17,853 |
18,561 |
19,111 |
||
Cash |
1,117 |
629 |
1,477 |
6,588 |
500 |
500 |
||
Other |
347 |
432 |
134 |
4 |
0 |
0 |
||
Current Liabilities |
|
|
(12,533) |
(16,005) |
(13,481) |
(16,388) |
(17,405) |
(26,337) |
Creditors |
(11,962) |
(12,729) |
(12,675) |
(15,834) |
(15,223) |
(15,832) |
||
Short term borrowings |
(522) |
(2,356) |
(567) |
(487) |
(2,182) |
(10,506) |
||
Provisions |
(49) |
(920) |
(239) |
(67) |
0 |
0 |
||
Long Term Liabilities |
|
|
(12,754) |
(12,602) |
(11,760) |
(17,021) |
(10,403) |
(14,365) |
Long term borrowings |
(8,889) |
(7,857) |
(7,065) |
(7,755) |
(1,091) |
(5,253) |
||
Other long term liabilities |
(3,865) |
(4,745) |
(4,695) |
(9,266) |
(9,312) |
(9,112) |
||
Net Assets |
|
|
27,394 |
28,760 |
33,185 |
37,187 |
44,165 |
49,762 |
CASH FLOW |
||||||||
Operating Cash Flow |
|
|
9,250 |
3,528 |
8,667 |
10,804 |
12,010 |
12,696 |
Net Interest |
(714) |
(724) |
(740) |
(703) |
(559) |
(851) |
||
Tax |
(649) |
(1,552) |
(1,469) |
(2,022) |
(2,425) |
(2,502) |
||
Capex |
(1,433) |
(538) |
(924) |
(679) |
(7,887) |
(19,442) |
||
Acquisitions/disposals |
(154) |
(208) |
(103) |
(861) |
0 |
0 |
||
Financing |
(56) |
105 |
147 |
280 |
0 |
0 |
||
Dividends |
(1,585) |
(1,899) |
(1,978) |
(2,095) |
(2,257) |
(2,386) |
||
Net Cash Flow |
4,659 |
(1,288) |
3,600 |
4,724 |
(1,118) |
(12,486) |
||
Opening net debt/(cash) |
|
|
12,949 |
8,294 |
9,584 |
6,155 |
1,654 |
2,773 |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
(4) |
(2) |
(171) |
(223) |
(1)0 |
0 |
||
Closing net debt/(cash) |
|
|
8,294 |
9,584 |
6,155 |
1,654 |
2,773 |
15,259 |
Source: Edison Investment Research, Treatt data
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US |
Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia |
Wellington +64 (0)48 948 555 Level 15, 171 Featherston St Wellington 6011 New Zealand |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US |
Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia |
Wellington +64 (0)48 948 555 Level 15, 171 Featherston St Wellington 6011 New Zealand |